复方阿齐沙坦酯/氯噻酮药理作用研究进展

Pharmacological effect of azilsartan medoxomil /chlorthalidone tablet: research advances

复方阿齐沙坦酯/氯噻酮(azilsartan medoxomil/chlorthalidone,Edarbyclor)片剂,由一种AT1亚型血管紧张素Ⅱ受体阻滞剂阿齐沙坦酯和噻嗪类利尿剂氯噻酮构成,2011年12月获美国FDA批准用于抗高血压治疗。研究表明,该复方制剂较阿齐沙坦酯或氯噻酮单方具有更显著的降压效果。阿齐沙坦酯/氯噻酮具有独立降压机制,两者合用发挥协同降压的同时合理降低剂量,减少不良反应的发生率。本文综述了复方阿齐沙坦酯/氯噻酮片剂的药物作用机制,药物代谢动力学、安全性及临床研究进展。

Azilsartan medoxomil/chlorthalidone （Edarbyclor）tablet is a combined angiotensin receptor blocker and thiazidelike diuretic, and was approved on December 2011 by US FDA for hypertension management. The combination of azilsartan medoxomil and chlorthalidone has efficacy in lowering blood pressure（BP） in hypertensive patients to a greater degree than azilsartan medoxomil or chlorthalidone alone. The two active ingredients of Edarbyclor have two separate mechanisms involved in lowering BP with less dosage and incidence of adverse effect. This article reviews mechanism of action, pharmacokinetics, safety evaluation and advances in clinical research of azilsartan medoxomil/chlorthalidone.